Shareholding disclosure

Catalyst Pharmaceuticals, Inc

Declared position

9.391%

Threshold

Crossed upwards

Timeline

Published

29.04.2026

Transaction

24.04.2026

Voting rights breakdown

Voting rights acquired9.391%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

ZA01-000000000S0H1

Beneficial owner

Catalyst Pharmaceuticals, Inc

Declared address

Catalyst Pharmaceuticals, Inc., Coral Gables, Florida, US

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Catalyst Pharmaceuticals, Inc

Santhera Pharmaceuticals Holding AG29.04.2026ZA01-000000000S0H1

Disclosure summary

Catalyst Pharmaceuticals, Inc disclosed a holding in Santhera Pharmaceuticals Holding AG on the acquisition side, published by SIX Exchange Regulation on 29.04.2026, at 9.391% of voting rights. Notice category: Single shareholder.

Disclosed position

9.391%

Voting rights acquired

Voting rights acquired9.391%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Catalyst Pharmaceuticals, Inc disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 29.04.2026.

Publication date29.04.2026

Transaction date24.04.2026

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerCatalyst Pharmaceuticals, Inc

Declared addressCatalyst Pharmaceuticals, Inc., Coral Gables, Florida, US

CategorySingle shareholder

Voting rights acquired9.391%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDZA01-000000000S0H1

Source: SIX Exchange Regulation · Publication date: 29.04.2026

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open